The Troubling Truth of Mpox

Credit: WHO/Lindsay Mackenzie
  • Opinion by Oritro Karim (new york)
  • Inter Press Service

Mpox, formerly known as monkeypox, is an epidemic that has grown exponentially in severity over the past two years.

Originating in Central Africa in 1970, rates of infection have risen significantly since late 2023, with a new variant of the infection, known as clade 1 Mpox, infecting over 17,000 people in the Democratic Republic of Congo.

These cases have generated increasing alarm, so much so that the World Health Organization has declared Mpox to be a worldwide public health emergency. Shortly after this declaration, the first case of clade 1 Mpox was reported in Sweden which greatly elevated global concern of a worldwide epidemic.

Mpox, once thought to be a primary concern for solely the Democratic Republic of Congo, has begun to spread to neighboring countries and has been rising in rates of death due to infection.

The director-general for the Worldwide Health Organization, Dr. Tedros Adhanom Ghebreyesus, states, "The emergence of a new clade of Mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighboring countries are very worrying. On top of outbreaks of other Mpox clades in DRC and other countries in Africa, it's clear that a coordinated international response is needed to stop these outbreaks and save lives".

It is imperative for the world to understand the graveness of the Mpox epidemic and funnel resources into stopping rates of infection as well as providing widespread access to treatment.

Although most fatalities have remained in the Democratic Republic of Congo, reports of infection have increased dramatically in Burundi, Nigeria, Central African Republic, and the Republic of Congo. There have even been reports of mpox spreading over Asian borders in small quantities, into Taiwan, Pakistan, and the Philippines.

It is interesting to note that the World Health Organization had organized an effort in combating the 2022-2023 Mpox outbreak for a different clade, and when that effort had concluded, a different clade had arisen and began to infect people all throughout Africa.

It is apparent from this prior development that a long-term effort is needed to combat Mpox as it is a disease that is resilient to change and will continually evolve. Dr. Tedros states that "stopping these outbreaks will require a tailored and comprehensive response, with communities at the center, as always". Therefore, it is necessary to adjust for these changes accordingly and continue to treat Mpox with the seriousness it deserves.

Recently, the director-general has authorized for an emergency use vaccine to be distributed in lower income countries. This is a crucial first step as Mpox cases are most prevalent in underdeveloped or developing African countries. Furthermore, it is important to target the countries of highest concern first in order to stop the spread to other parts of the world.

Currently the World Health Organization has set up specific efforts in order to combat Mpox. One such example is that WHO has released 1.4 million dollars from their emergency contingency fund to fight this epidemic, expecting to release more in the coming weeks. Additionally, WHO is working with vaccine manufacturers around the world in order to find the most effective and accessible treatments.

Furthermore, there has been a focus put into surveillance of the disease and exactly how many are infected. This will be particularly crucial in the process of fighting Mpox as right now, the number of infected people are approximations as many cases have not been reported.

Although the current efforts by WHO are a step in the right direction, there is much more action needed to eradicate the Mpox epidemic.

It is important that donors contribute to this effort as WHO estimates that about 15 million dollars will be needed for their multi step plan.

IPS UN Bureau


Follow IPS News UN Bureau on Instagram

© Inter Press Service (2024) — All Rights ReservedOriginal source: Inter Press Service